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Suboptimal early life nutrition can have a life-long effect on the risk to develop 
obesity and its associated detrimental health afflictions such as type-2 diabetes, 
atherosclerosis, and cardiovascular disease [24-31]. Mother’s own milk with vitamin K 
supplementation is considered the most optimal source of early life nutrition for 
nearly all term infants [50, 56, 57]. The alternative, namely infant milk formula, is 
(among other long-term health effects [28-31]) epidemiologically associated with a 
higher incidence of childhood, adolescent, and adulthood obesity [24, 25], and higher 
blood pressure and plasma cholesterol levels in adulthood [26, 27]. It appears that 
differences between breast-feeding and formula-feeding, whatever they may be, are 
associated with persisting effects on later life health [24-31]. Increasing the initiation 
rate and duration of breast-feeding are expected to decrease the aforementioned non-
communicable disease risk factors [54]. In the Netherlands, the rate and duration of 
breast-feeding are mainly determined by socioeconomic and legislative factors [54-
56]. Alternatively, the gap between breast-fed and formula-fed infants, with regards 
to the incidence of later life obesity, could be narrowed by further ‘humanization’ or 
otherwise improvement of infant formulae [18, 72, 92, 237]. Preclinical research indicates 
that mimicking the physicochemical structure of human milk lipid globules in infant 
formula, versus control infant formula, lowers the body weight and fat mass gain in 
later life upon a Western-style diet challenge [8, 9, 80, 96]. In this thesis I aimed to 
determine possible mechanism(s) of metabolic programming of adult life body 
weight and fat mass gain after feeding mice an early life diet containing large 
phospholipid-coated lipid globules. 
 
The robustness and l imits of early l ife IMF-induced programming 
In a series of preclinical experiments, it was shown that mimicking the 
physicochemical structure of human milk fat globules in an IMF fed in early life 
lowered fat mass gain upon a Western-style diet challenge in later life [8, 9, 80, 96]. On 
a logical basis, it was not possible to conclude whether the observed lower fat mass 
(gain) was a consequence of a lower ‘response’ to the Western-style diet, or due to 
an incapability to gain fat mass per se [9, 80, 96]. Data in Chapter 2 showed that the 
beneficial effects of eIMF versus cIMF with regards to later life body weight and fat 
mass gain were transient when the exposure to a high-fat diet was continued [8]. This 
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observation provided evidence that the effects on body weight and fat mass gain 
were not due to an incapability to gain body weight and/or fat mass per se [238-240]. If 
this was the case, the effect could logically not have been transient [8]. This 
distinction is important as the inadequacy to respond to a high-fat diet (i.e. lower 
body weight and fat mass gain) may in fact indicate a pathological condition instead 
of a beneficial (programming) effect [171, 207, 210]. Data in Chapter 2 did not indicate 
signs of IMF-induced (long-term) pathology with regards to the assessed parameters 
[8]. Also peak body weight was similar between eIMF and cIMF-fed mice [8]. The 
observation that the programming effect (i.e. the ability to partially resist HFD-
induced weight gain) can be overruled by a prolonged exposure to a HFD challenge 
is therefore considered a sign that the mice are able to exhibit their natural (body 
weight accruing) phenotype to their full potential given sufficient time [8].  
 
Mice are born more altricial (immature, less developed) compared to humans, 
e.g. without developed ears and eyes [102]. In terms of brain development, the third 
trimester of human pregnancy approximately corresponds to murine postnatal day 
(PN) 0-10 [100, 101]. Artificial methods of rearing rat and mouse pups are colloquially 
named “pup in a cup” models [101, 241, 242]. These models are possible as early as 
postnatal day 1 through invasive methods [243]. Artificial rearing models versus 
standard dam rearing, however, may result in undesirable long-term consequences 
such as anxiety-like behavior [244] and thus by itself are a likely programming factor. 
I chose to avoid the inherent stress associated with artificial rearing models. A time 
period for the dietary intervention was chosen in Chapter 2-4 wherein pups eat food 
on their own. The programming diets were provided from PN16 onwards; the 
approximate age from which mouse pups are able to (and do) eat solid food by 
themselves [245]. In mice, the quantity of secreted milk reduces from PN17, and 
breast-feeding ceases entirely after PN22 [245]. Milk production and thereby milk 
feeding reduces earlier (and natural weaning then also occurs earlier) in smaller nests 
compared to larger nests [245]. The IMF diets were provided during the periweaning 
(PN16-21) and postweaning (PN21-42) period [8, 245, 246]. Plasma lipid data in 
Chapter 3, in particular the phospholipid levels, suggested that the weanlings had 
eaten from the IMF diets (shortly) prior to sampling at PN21. However, dietary 
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phospholipids may alter the phospholipid content of breast milk [247]. Thus, it cannot 
be stated conclusively whether the pups (mostly) ate the IMF diets during the 
periweaning period or not. It was not further tested which days within the PN16-42 
period were (non-) essential for the effects on later life body weight and fat mass 
gain. Others have shown that central mechanisms important in dietary preferences 
can be programmed in mice during the period PN21-28 [248]. It is assumed that IMF 
feeding does not impede or otherwise disturb breast-feeding and that eIMF’s long-
term beneficial effects on body weight and fat mass gain occurred in (fully) breast-
fed mice. If that assumption is valid, it indicates that eIMF acted independently from, 
or in combination with, breast-feeding in mice [8, 9, 80, 96]. If eIMF exerts a similar 
long-term beneficial effect on body weight and fat mass gain in humans, it may do 
so either with or without concomitant breast-feeding. Proving the long-term (multi-
decade) efficacy of eIMF in humans is not practically feasible. As per European law, 
it is required to show the (short-term) safety and tolerance of a new infant formula 
prior to allowing it on the commercial market. The eIMF was recently evaluated for 
safety and tolerance in a trial (Dutch Trial Register NTR3683) [249]. The eIMF was 
found to be safe, and well tolerated (i.e. number, severity, or relatedness of adverse 
events) [249]. In healthy infants, early life growth (daily weight gain) was equivalent 
between eIMF and commercially available control IMF [249]. Follow up (5 years) of 
infants fed eIMF in early life (Dutch Trial Register NTR5538) is expected to provide 
insights into body mass index, and the prevalence of overweight and obesity at 3, 4, 
and 5 years of age.  
 
Energy balance 
After establishing that the long-term effects on body weight and fat mass gain 
were not a result of an incapability to store fat mass [8, 207, 238-240], possible underlying 
mechanisms with regard to body weight and fat mass gain were explored in Chapter 
3 and 4. Fundamentally, weight gain by fat mass gain is the result of a positive energy 
balance of the organism [250], i.e. energy intake exceeds total energy expenditure. 
Energy intake is determined by food intake and the efficiency of absorption. Total 
energy expenditure is the sum of basal metabolic rate, adaptive thermogenesis and 
physical activity [250]. The basal (resting) metabolic rate is the amount of energy 
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consumed at rest by the myriad of biochemical processes necessary to sustain life at 
thermoneutrality [150, 250]. When adequately corrected for tissue weights, only subtle 
changes in basal metabolism occur due to age [150]. Adipose tissue consumes very 
low amounts of energy per day for its basal metabolism [150]. Whole body basal 
metabolic rate (when expressed per kg) may therefore decrease upon fat mass gain. 
The remainder of energy expenditure depends on heat loss to the environment and 
bodily activity and is highly variable. The concept of ‘slow metabolism’, i.e. a low 
energy expenditure per kg of body weight, is clearly erroneous [251]. This concept led 
to years of futile clinical studies on obese humans seeking to find obese individuals 
with a slow metabolism; none were found [251]. A plethora of studies indicate that 
total energy intake and/or energy intake per unit of body weight was lower in free-
living obese versus normal weight human subjects [252-259]. The premise that obesity 
is not linked to food intake is, however, absurd and misleading. The contribution of 
dietary (energy) intake to weight gain and obesity is heavily confounded by the 
difficulty of attaining accurate measurements of caloric intake and by human 
psychology [250, 260, 261]. Caloric intake is underreported by as much as 47%, and 
physical activity is overreported by as much as 51% by obese subjects [260]. The 
discrepancy between self-reported energy intake and actual intake is not unique to 
the obese, as it is also seen in athletes [261]. It appears that self-reported data on energy 
intake and energy expenditure is not sufficiently accurate to assess energy balance 
[260, 261]. Using doubly-labeled (heavy) water, it is possible to calculate total energy 
expenditure in free-living humans [262]. Using that method, total energy expenditure 
in men and women increases steadily with increasing BMI [263]. Under controlled 
metabolic chamber conditions, both the basal metabolic rate, and the metabolic rate 
during sedentary activities is higher in obese versus normal-weight subjects [264]. In 
men and women, a clear relationship exists between investigator-measured caloric 
intake and weight gain or weight loss [165]. Between 1980 and 2005, physical activity 
expenditure (measured by doubly-labeled water) has not declined in Europe and 
North America [265]. The additional costs of moving a higher body weight and the 
additional (lean) body mass in the obese may offset less overall movement [265]. 
Energy expenditure in Western societies is not lower compared to that of inhabitants 
of third world countries, and not relatively lower compared to wild terrestrial 
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mammals [265]. It may still be that total energy expenditure per person was higher 
prior to 1980, but no accurate data exists to (dis)prove this. Estimations of total 
energy fluxes from 1980 onwards indicate that substantial increases in total energy 
intake are more likely to have driven the increases in body weight rather than a 
decrease in energy expenditure [6, 265]. Preventing (too) high energy intake is key and 
early life programming provides a unique opportunity to set later life susceptibility 
to weight gain and subsequent obesity [24-27]. 
 
Energy balance by expenditure 
The basal metabolic rate has been presented as a static number, highly dependent 
on tissue mass and (to a minor extent) age in humans [150]. The recent increase in the 
prevalence of overweight among Western European citizens is more likely to be 
caused by a higher energy intake than a lower energy expenditure [6, 265]. For reasons 
of completeness, I will nonetheless discuss the biological plausibility that later life 
energy expenditure can be affected by early life factors. The basal metabolic rate of 
animals is responsible for a significant part of total energy expenditure. One would 
expect, given that basal metabolic rate is a large contributor to total energy 
expenditure, that it strongly affects reproductive success and thereby has a high 
heritability [266]. However, in wild leaf-eared mice (Phyllotis darwini) heritability of 
basal metabolic rate is low, and is associated instead more strongly with maternal 
and environmental factors [267, 268]. In zebra finches (Taeniopygia guttata), later life 
basal metabolic rate can be programmed in early life by altering the growth rates via 
the diet [266]. It appears that later life basal metabolic rate is higher when finches are 
primed in early life with a poor quality diet, and fed a high-quality diet in later life, 
compared to when diets match [266]. In rats, protein restriction during pregnancy 
and/or lactation results in permanently growth-retarded offspring with permanent 
and selective changes in organ weights, versus ad libitum fed controls [269]. Essential 
organs like the brain and lungs were unaffected, whereas the liver, pancreas, skeletal 
muscles and the spleen were smaller and lighter upon protein restriction [269]. In 
growth-retarded offspring, liver metabolism appears permanently biased towards a 
starved-like condition in that the activities of key hepatic enzymes of glycolysis were 
lower and of gluconeogenesis were higher [269]. Individuals with smaller organs will 
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have a lower basal metabolic rate at the expense of a lower maximal metabolic rate 
[268]. Energy spent on movement, or the amount of spontaneous movement (i.e. 
pacing or fidgeting), may be a modifiable trait [270]. Rat pups, born from 
undernourished versus nourished mothers and weaned on an ad lib control diet, were 
less active in adolescence (PN35) and later life (PN145 and PN420) [270]. This later 
life effect was exacerbated by high-fat diet feeding [270]. A similar phenomenon was 
observed in mice [271]. Mouse pups, born from protein-malnourished versus 
nourished dams, and breast-fed (cross-fostered) by protein-nourished dams, engaged 
in less voluntary wheel running exercise in later life [271]. Mouse pups, breast-fed in 
litters of 4 pups versus 9 pups (a model of postnatal overnutrition; i.e. more milk per 
pup), had lower bodily activity and lower energy expenditure in later life (PN180) 
[272]. Data in Chapter 2 indicated that early life eIMF feeding, under well-nourished 
conditions, did not significantly change later life (PN154) energy expenditure (per 
kg body weight) in HFD-fed sedentary males [8]. The reader is advised to be critical 
of measurements involving (indirect) calorimetry [251]. Subtle differences in energy 
expenditure (and intake, for that matter) can account for marked differences in 
accumulated expenditure over time [251]. Such subtle differences in energy 
expenditure can fall below the limits of the discriminatory capacity of the technique 
used to assess it [251]. Interestingly, the maximum mitochondrial oxidative capacity 
in eIMF versus cIMF-fed mice, fed high-fat diet in later life, was higher in skeletal 
(M. tibialis) muscle and retroperitoneal white adipose tissue (at PN98) [166]. These 
findings indicate that early life environmental factors such as maternal 
undernutrition [270, 271], postnatal overnutrition [272], and even the postnatal diet’s 
physicochemical structure [166], can change parameters of energy expenditure. It is 
unclear whether the observed differences in mitochondrial oxidative capacity [166] 
underlie the long-term beneficial effects on body weight and fat mass gain. Even if 
this is the case, it still remains unclear how a relatively subtle change in the 
physicochemical structure of an early life diet changes the later life mitochondrial 
capacity. Chapter 3 showed, at least in liver tissue, that surrogate markers of 
mitochondrial capacity were already higher during eIMF-feeding. It is, however, 
unreasonable to assume that a higher capacity to utilize substrates always results in 
a higher long-term rate of substrate utilization (i.e. a higher energy expenditure). A 
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dramatic example of this is seen in endurance athletes, who have a much higher total 
energy expenditure during competitions compared to during the (pre-competition) 
training season [261]. Endurance training in elderly subjects (aged 56-78 years) 
notably increases maximum oxygen consumption without a concomitant increase in 
total energy expenditure [273]. Similarly, aerobic training in young non-obese 
sedentary women increases maximum oxygen consumption without increasing the 
total energy expenditure [274]. In both studies, it is thought that the energy costs of 
training are compensated for by a reduction in activity outside of the training sessions 
[273, 274]. These studies do not argue against the usefulness of endurance training for 
young and old subjects. Endurance exercise promotes mitochondrial biogenesis in 
skeletal muscle and enhances muscle oxidative capacity [275]. By inference, it may 
thus well be that a higher mitochondrial oxidative capacity in (for instance, skeletal 
muscle) does not automatically result in a higher (whole body) total energy 
expenditure. It appears that relatively short bouts of higher substrate utilization are 
sufficient to increase mitochondrial oxidative capacity. It is unclear why eIMF-fed 
mice have higher hepatic levels of proteins involved in fatty acid oxidation (Chapter 
3). It is also not clear which mechanism could underly the higher muscle and adipose 
tissue mitochondrial capacity in eIMF versus cIMF-primed mice in later life during 
WSD-feeding [166]. Vors et al, administered a breakfast comprising of (biochemically 
identical) emulsified versus spread fats to normal weight and obese men [97]. Stable 
isotopically labelled triglycerides were added to these breakfasts. They reported that 
emulsified versus spread fat was more rapidly absorbed, led to larger chylomicrons, 
and a sharper 13CO2 appearance in obese subjects [97]. These observations suggested 
that emulsified versus spread fats, despite being biochemically identical, are more 
rapidly oxidized (and converted to stable isotopically labeled CO2) [97]. This is in 
agreement with the notion that rapid fat absorption results in larger chylomicrons, 
from which the triglycerides are more rapidly taken up by extra-hepatic tissues [167, 
172, 175, 176]. Whether this would then coincide with a higher mitochondrial capacity is 
unclear. Vors et al reported that total fat oxidation was similar after ingestion of 
emulsified or spread fat [97]. It may be that the peak rate of fatty acid oxidation is 
different after ingesting emulsified or spread fat. I hypothesize that rapid fat 
absorption (in early life) results in short bouts of high peripheral lipid oxidation. 
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These short bouts may then (temporarily) increase mitochondrial oxidative capacity 
in extra-hepatic tissues. I cannot, with reasonable certainty, state whether this would 
then explain the differences in liver mitochondrial enzyme levels between eIMF and 
cIMF-fed mice in Chapter 3. I hypothesize that the higher oxidative capacity in 
muscle tissue [166] and the higher levels of proteins involved in fatty acid oxidation 
(Chapter 3) are a consequence of a difference in the handling of absorbed fats. It is 
unclear whether the observed differences in mitochondrial capacity are 
mechanistically related to the long-term effects on body weight and fat mass gain. 
Alternatively, it is possible that whatever factor is responsible for the effects on 
mitochondria, simultaneously and independently underlies the long-term effects on 
body weight and fat mass gain per se. The rate of fat absorption is linked to the onset 
of the sensation of hunger in obese but not in lean subjects [97]. This now makes it 
tempting to speculate that an aspect of the absorption and/or postprandial handling 
of fats underlies the effect on mitochondria and perhaps also on food intake. 
 
Energy balance by intake 
Under conditions of food availability, food intake occurs at the intersect between 
free will and determinism [276, 277]. Decisions on total energy intake may appear to be 
free to the individual, but are nonetheless unquestionably subject to (occasionally 
strong) biological regulation and environmental influences [276-283]. A seemingly 
perpetual war is waged over the most ideal human diet; low-carb, low-fat, keto, 
paleo, low-protein, high-protein, plant-based, vegetarian, vegan and endless other 
diets with disputed short-term and long-term effects on health [165]. These diets 
arguably cause public confusion and they may lower the (public) trust in (nutritional) 
science. The seemingly common denominator of these widely diverse diets is the 
avoidance of so-called ‘ultra-processed foods’ [165, 284]. These are described as 
“formulations mostly of cheap industrial sources of dietary energy and nutrients plus 
additives, using a series of processes”, and contain low amounts of whole foods [165]. 
Men and women offered (ad libitum) an ultra-processed diet versus a mostly 
unprocessed diet consumed more calories and gained body weight [165]. These 
observations suggest that attributes of a meal determine (to some extent) satiety. This 
notion is underlined by the observation that obese (but not lean) subjects, when 
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offered a breakfast containing spread fat versus (biochemically identical, but 
physicochemically dissimilar) emulsified fat, felt more hungry prior to lunch [97]. 
Clear differences exist with regards to the rate of fat absorption, when comparing 
spread versus emulsified fat [97]. This concept has been coined ‘slow versus fast fat’ 
[68], as a homage to slow and fast carbohydrates. In Chapter 2, data indicated that 
eIMF-programmed mice ate slightly (albeit non-significantly) less of the high-fat 
diet [8]. Food intake did correlate with long-term (PN42-147) weight gain [8]. The 
hypothesis that eIMF’s long-term effects on body weight and fat mass gain are 
caused by a lower food intake is plausible. Given the lack of statistical significance, 
I cannot conclude with certainty that this is indeed the case. Even if this is the case, 
then it remains unclear how a relatively subtle change in the physicochemical 
structure of an early life diet changes later life food intake.  
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Understanding the underlying mechanisms of eIMF-induced 
programming 
Upon absorption, dietary fats are packaged into lipoprotein particles 
(chylomicrons) by the gut [136]. These particles are subsequently secreted into the 
lymph [136]. Lipoprotein particles consist of apolipoproteins and a phospholipid 
monolayer containing amphipathic molecules (such as cholesterol) [138, 175]. The type 
of apolipoprotein B (ApoB) is unique to the type of particle; ApoB48 for 
chylomicrons and ApoB100 for VLDL particles in humans [285]. Chylomicron 
particles typically contain one ApoB48 protein. The lipoprotein particle membrane 
encapsulates a core consisting of neutral lipids [138]. The diameter of chylomicron 
particles during fasting and during active lipid absorption depends (among others) 
on the quantity of biliary phospholipids [136]. In adulthood, active lipid absorption 
increases the diameter of chylomicrons [95, 97, 136]. By increasing the diameter, the 
volume-to-surface area ratio is increased, increasing the lipid carrying capacity [286]. 
It is not clear whether dietary phospholipids (such as those present in human milk 
and eIMF) similarly impact the diameter of lymphatic chylomicrons in infants. 
Breast-fed infants, versus formula-fed infants, have a higher plasma TG-to-ApoB48 
ratio [95]. Triglycerides make up the neutral core (the volume) and ApoB48 is 
primarily stretched across the phospholipid layer (the surface area) [285]. This 
suggests that chylomicrons in breast-fed versus formula-fed infants are larger and 
carry a larger fat load per particle [95]. Triglycerides (TG), present in the neutral core 
of chylomicrons, are enzymatically hydrolyzed to free fatty acids by lipoprotein 
lipase (LPL) [172, 173]. Free fatty acids are occasionally referred to as non-esterified 
fatty acids (NEFA). LPL is present in the vascular bed of extrahepatic tissues 
including the heart, skeletal muscle and adipose tissue [172, 173]. The rate of TG 
hydrolysis (by LPL) is higher when chylomicrons have a larger diameter and thus a 
higher volume-to-surface area ratio [97]. This peculiar characteristic aids in the rapid 
clearance of plasma TGs following a fat laden meal [95, 97]. In adult men, rapid 
absorption of fat, versus slower absorption of fat, results in larger postabsorptive 
chylomicrons, which in turn lead to (transiently) higher plasma NEFA levels [97]. It 
is not known whether differences in the rate of absorption such as those seen in 
breast-fed infants versus formula-fed infants [95], have a lasting effect on the rate of 
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absorption in later life. Given the data collected in adult men [97] and infants [95], it 
was originally hypothesized that eIMF would program the rate of fat absorption. Our 
present data, however, do not support this notion. Instead, data in Chapter 4 do 
demonstrate that postabsorptive lipid handling is a trait that is modifiable by early 
life feeding with eIMF. Similar to what was seen in adult men [97], the effects on 
postabsorptive lipid handling seen in Chapter 4 are unique to high-fat diet feeding. 
No explanation currently exists for this HFD-exclusivity. If the long-term effects of 
eIMF on body weight and fat mass gain rely on postabsorptive lipid handling, it may 
be that weight gain from fat is affected, whereas weight gain from non-fat is not or 
to a lesser extent. Alternatively, it may be that the regulation of postabsorptive 
metabolism differs between low-fat and high-fat diet fed mice (and men). In humans, 
adipose tissue and heparin-releasable LPL activity is much higher in obese versus 
lean subjects [287]. Weight loss in obese subjects further increases adipose tissue LPL 
activity, returning to its pre-weight loss levels upon rebound weight gain [177]. It has 
been suggested that LPL plays an important role in the ‘adipostat’, a hypothetical 
regulatory system controlling how much fat is stored in the body [287]. To some 
extent, LPL protein levels are regulated via epigenetic means by DNA methylation 
of the LPL promotor region [173]. The degree of LPL promotor methylation positively 
associates with abnormalities of the metabolic profile and basal and postprandial 
triglycerides [173]. In healthy and obese men and women, major determinants of 
adipose tissue LPL activity are obesity itself and its associated hormones (leptin and 
insulin) [288, 289]. In these human studies, it is not clear what is cause and what is effect 
[173, 288, 289]. In addition to the long-term regulatory mechanisms of LPL [173, 288, 289], 
short-term regulatory mechanisms exist that are affected by fasting and the 
postabsorptive state [290-293]. In obese but not in lean mice, LPL activity is increased 
in skeletal muscles [290] and adipose tissue (only per gram of adipose tissue protein, 
not per cell) by leptin infusion [290, 291]. In rats, adipose tissue LPL activity is down-
regulated at the post-translational level by fasting within hours [292]. The nutritional 
state is thought to modify LPL activity via ANGPTL4, GPIHBP1 and LMF1 [293]. 
ANGPTL4, also known as Fiaf is an endogenous inhibitor of LPL that is secreted 
into the blood stream by the liver, intestines, white adipose tissue and brown adipose 
tissue [294]. It is thought that ANGPTL4 inhibits LPL by promoting the conversion of 
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active LPL dimers into inactive monomers [295]. High expression levels of ANGPTL4 
(and subsequent inhibition of LPL) is suggested to be responsible for the lean 
phenotype of germ-free mice versus conventional mice [294]. Intestinal ANGPTL4 
expression is selectively suppressed in conventional mice [294]. Germ-free mice 
lacking ANGPTL4 have similar amounts of body fat compared to conventional mice 
[294]. Despite much higher adipose tissue and heart LPL activity levels (in 
conventional versus germ-free mice) [294], and thereby shorter chylomicron plasma 
residence time, plasma triglycerides are similar between these mice [296]. This 
discrepancy is explained, at least in part, by the higher VLDL-TG secretion rates 
seen in conventional versus germ-free mice [296]. This possibly illustrates an elegant 
regulatory system maintaining plasma TG (and NEFA) levels by increasing VLDL 
secretion upon shorter chylomicron residence time. These data do not rule out the 
myriad of other mechanisms through which the microbiota (in conventional versus 
germ-free mice) may or may not affect adiposity. Gross (3~6 fold) transgenic 
overexpression of ANGPTL4 leads to a reduction in adipose tissue weight and body 
weight which is at least in part explained by a higher fatty acid oxidation and 
uncoupling in adipose tissue [297]. These data suggest that postabsorptive lipid 
handling, mediated via the endogenous inhibition of LPL, can impact whole-body 
adiposity and body weight [294, 296, 297]. LPL is transported across and anchored to the 
capillary endothelial surface by GPIHBP1 [298]. The active (homodimer) form of LPL 
is stabilized by GPIHBP1 [295]. Absence of or specific mutations of GPIHBP1 lead 
to LPL dysfunction and severe hypertriglyceridemia in humans [299]. Interestingly, 
the amount of GPIHBP1 protein in the visceral adipose tissue of men and women 
correlates negatively with plasma insulin and glucose levels [298]. Fasting increases 
GPIHBP1 expression levels in the heart, white adipose tissue and brown adipose 
tissue [300]. GPIHBP1 expression is specifically induced by PPARγ agonists [300]. It is 
not clear to what extent GPIHBP1 is relevant for LPL activity under physiological 
conditions [295]. The antidiabetic thiazolidinedione BRL 49653, a high affinity 
PPARγ agonist, induced LPL expression in rat adipose tissue [301]. A sequence 
element (PPAR response element; PPRE) is present in the human LPL promoter. 
This PPRE is responsible for the functional responsiveness of the adipose tissue to 
fibrates and thiazolidinediones [301]. In humans, LPL synthesis in adipose tissue is 
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relatively inefficient as approx. 25-50% of the synthesized polypeptide forms 
inactive, high-molecular weight aggregates destined for degradation [295]. LMF1 is 
an endoplasmic reticulum chaperone involved in the maturation of homodimeric 
lipases (such as LPL) [295]. In mice, Lmf1 overexpression increases LPL activity 
without changing the total amount of LPL protein [302]. It is not clear to what extent, 
if at all, LMF1 is involved in the regulation of LPL activity under physiological 
conditions. 
 
The data presented in Chapter 2-4 [8], and in the manuscript of Kodde et al [166] 
make it tempting to speculate that eIMF exerts its long-term effects via the LPL 
regulatory system [294, 296, 297]. Early life eIMF feeding results in higher gene and 
protein expression of mitochondrial oxidative capacity markers in skeletal muscle 
and adipose tissue in later life during HFD feeding [166]. Concomitantly, early life 
eIMF feeding changes postabsorptive lipid handling in later life during HFD feeding. 
Early life eIMF feeding lowers later life PPARγ expression in white adipose tissue 
depots during HFD feeding [96], which may lower GPIHBP1 expression levels [300]. 
Currently, there is no data indicating that the microbiota is involved in the observed 
long-term effects of eIMF on body weight and fat mass gain. This would have to be 
tested in an independent study. Given the body of data accrued, it appears more 
plausible that the proposed mechanism of action of eIMF lies in the LPL regulatory 
system. The latter may be responsible for the observed long-term effects on 
mitochondrial capacity, and body weight and fat mas gain. This hypothesis will need 
to be tested in an independent study. 
 
Several questions remain open at this point. Is the proposed mechanism of action 
unique to eIMF, or does it also underlie the long-term effects of breast-feeding per 
se? Are the differences in postabsorptive metabolism caused by differences in LPL 
activity [294, 297]? If this is the case; are these differences in LPL activity caused by 
DNA methylation of LPL [173] and/or ANGPTL4 [303]?  
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Vitamin K interactions  
Vitamin K (VK) is a fat-soluble vitamin which facilitates blood coagulation by 
activating clotting factors II (prothrombin), VII (proconvertin), IX (Christmas) and 
X (Stuart–Prower), and plasma Protein C, S and Z in the liver [71, 111]. VK has 
functions beyond blood coagulation, such as in the carboxylation of osteocalcin and 
matrix Gla-protein [304]. In humans, VK can be obtained via the diet [182]. Colorectal 
(microbially synthesized) VK absorption is poor [182]. Vitamin K (VK) deficiency 
(VKD) can cause bleedings (VKDB) [111]. At birth, neonates have low amounts of 
VK stores due to limited placental transfer of VK and due to the limited capacity to 
store VK [53]. Human milk typically contains low concentrations of VK. The result 
of the combination of these unfortunate factors is that unsupplemented breast-fed 
neonates are vulnerable to develop VKDB and its consequences [111]. In ~50% of 
neonatal VKDB cases, bleedings occur intracranially and associate with high 
morbidity and mortality [53]. To prevent VKD, breast-fed newborns are 
prophylactically supplemented with VK [52]. Formula-fed infants are typically not 
supplemented with VK, as the formula provides sufficient VK. In spite of 
supplementation, VKDB empirically occurs more often in breast-fed infants with 
(yet undiagnosed) impairments of bile flow, such as biliary atresia [52, 53, 109, 112, 113]. It 
appears that formula-feeding protects infants, including those with yet unidentified 
cholestasis, from VKDB [52]. This observation is puzzling, as the VK dosages are 
similar or even higher for supplemented breast-fed infants versus unsupplemented 
formula-fed infants. In Chapter 5, the hypothesis that (human milk) cholesterol 
disrupts vitamin K absorption was tested. Data in Chapter 5 suggest that dietary 
cholesterol may be responsible for the aforementioned observation. These data were 
obtained by feeding rats for 4 days a chow diet with or without cholesterol (chronic 
study). This is in agreement with experimental data obtained by others [114, 179, 187]. 
Upon testing the VK absorption using stable isotopically-labeled VK (acute study), 
plasma VK levels following human milk ingestion were paradoxically higher 
compared with plasma VK levels following infant formula ingestion. This is 
seemingly not compatible with the notion that formula feeding is the most effective 
prophylaxis to prevent VKDB [52, 111]. Ezetimibe, the NPC1L1 inhibitor known to 
disrupt cholesterol and VK absorption [71, 179, 186, 191], was used as a control. In the 
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‘chronic study’, the addition of ezetimibe to the high-cholesterol diet did not further 
lower plasma VK levels. It is undisputed that ezetimibe is able to disrupt the 
absorption of cholesterol and VK [179, 191]. However, it has been noted that under 
certain conditions, ezetimibe cannot further inhibit absorption if the absorption is 
already inhibited via other means [192]. It may be that high-cholesterol feeding inhibits 
VK absorption, and that ezetimibe cannot further inhibit this process. In the ‘acute 
study’, the group fed a diet containing cholesterol and ezetimibe had a similar plasma 
VK response as the group fed the same diet without ezetimibe. This study lacked a 
group fed a low-cholesterol diet, thus it is not possible to speculate whether the 
absence of ezetimibe’s effect is due to saturation of the inhibition [192]. Given the 
observations in Chapter 5, it appears likely that cholesterol can disrupt the 
absorption of VK in rats. Whether this is the reason why VKDB occurs more often 
in breast-fed infants with (yet undiagnosed) impairments of bile flow remains up for 
discussion and requires a new study.  
General discussion and conclusion 
165 
7 
Spontaneous murine l iver disease 
Throughout Chapter 2-4, a standard inbred mouse strain (C57BL/6JOlaHsd; a 
substrain of C57BL/6J [197]) was employed [8, 198]. These mice were fed so-called 
‘semisynthetic’ diets made from purified ingredients [118]. The composition of these 
diets was based on guidelines for rodent diets from the American Institute of 
Nutrition (AIN) [118]. Occasionally a high within-group variability in liver weight 
was noted. This was attributed to natural variability, though it was speculated that it 
may be caused by social hierarchy ranks [198]. In Chapter 6 this notion was 
challenged in a series of experiments designed to test whether the observed 
variability in liver weight was pathological and if so, how it could be detected in 
other experiments. 
 
Semisynthetic diets are manufactured from purified ingredients such as soybean 
oil, sucrose, casein and maltodextrin [118]. Semisynthetic control diets fulfil all known 
nutritional requirements of a mouse [118]. This manufacturing method allows 
researchers to easily manipulate the macro- and micronutrient composition of the 
diet, such as in a high-fat diet or a methionine- and choline-deficient diet. The usage 
of purified ingredients minimizes variability between food batches [118] and allows 
for fair comparisons between studies. Non-purified rodent diets (chow) are typically 
made from natural products such as wheatfeed, dehulled soybean meal, barley, and 
fish meal. These natural products inherently show natural and seasonal variability in 
their exact composition. Chow diets have (subtle) differences between batches [118], 
making comparisons between studies more complicated. Chow diets are primarily 
used due to their low costs (compared to semisynthetic diets) while still fulfilling all 
known nutritional requirements of the mouse. It is likely that chow diets contain a 
more diverse array of (nutritional) components. It has been noted that mice fed a 
semisynthetic diet (AIN-93G) compared to a non-purified (chow) control diet have 
a lower liver mass [235]. The rationale behind using inbred mouse strains and 
semisynthetic diets is to minimize genetic and environmental heterogeneity in 
experimental models of human diseases. In spite of these efforts, (occasionally high) 
phenotypic heterogeneity has been observed in inbred C57BL/6J mice in response 
to (semisynthetic) high-fat diets [171, 210, 305].  
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ApoE*3Leiden.CETP mice (C57BL/6J background strain) show an extremely 
heterogenic response to a (semisynthetic) high-fat high-cholesterol diet with regards 
to body weight, and lipid and glucose metabolism [213]. It is now recognized that this 
phenotypic heterogeneity is, at least in part, caused by the presence of distinct 
subpopulations within cohorts of mice [207, 213]. These sub-cohorts are named 
‘responders’ (R) and ‘non-responders’ (NR) (occasionally ‘low-responder’) [207]. 
ApoE*3Leiden.CETP mice are typically categorized into the aforementioned groups 
at PN42, when they are still fed chow, based on an arbitrary plasma TG or TC cut-
off value [207]. In later life, NR versus R mice under identical experimental conditions 
develop a more severe inflammatory liver condition, lower liver weight, higher liver 
TG, higher plasma liver enzymes and higher plasma bile acids [207]. The NR 
phenotype occurs in approx. 25% of apoE*3Leiden.CETP mice [207] (TNO DEC 3068, 3095, 
3112, 3126). Studies using this mouse strain do not always disclose whether the ‘non-
responders’ have been excluded from analyses. It was hypothesized that the NR 
phenotype was due to a low ApoE*3Leiden (TNO DEC 3068) or a low CETP expression 
[207]. Recently, it was demonstrated that CETP activity was similar in NR and R mice 
[207]. Up till now, it has remained unclear what causes the NR phenotype in 
ApoE*3Leiden.CETP mice [207, 213]. Without a clear understanding of why the ‘NR’ 
phenotype occurs, it seems ethically challenging and scientifically questionable to 
exclude 25% of a cohort. From the point of animal welfare (replacement, reduction, 
refinement; the 3Rs), the exclusion of 25% of mice is undesirable [306]. Nonetheless, 
retaining ‘NR’ in cohorts may lower discriminatory capacity of studies (i.e. statistical 
power) [129], which also goes against animal welfare [306]. 
 
Substantial neurochemical variability has been noted in C57BL/6J, but not in 
mouse strains NMRI, BALB/c, ICR CD1, NUDE, NOD-SCID, and SV 129 [211, 212]. 
Approximately 25% of C57BL/6J mice have threefold elevated cerebral glutamine 
levels, with concomitantly lower myoinositol, taurine and total choline 
independent of diet or superimposed genetic manipulation to model human disease 
states [211, 212]. In the Q140 knock-in mouse model of Huntington’s disease 
(C57BL/6J background strain) and its WT control group, (unspecified) high brain 
glutamine levels were also seen in some mice but not in others [307]. These mice were 
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excluded from subsequent analyses [307-309]. Such large differences in glutamine were 
well in excess of any treatment effect observed in studies performed at the research 
center in question [212]. Glutamine can be synthesized in the central nervous system 
from ammonia via the astrocyte-specific enzyme glutamine synthethase [212]. 
Elevated glutamine/glutamate peaks, coupled with lower myo-inositol and choline 
peaks (measured noninvasively using 1H-MRS) may represent disturbances in cell-
volume homeostasis secondary to brain hyperammonemia [310]. Clinically, this is 
referred to as ‘hepatic encephalopathy’ (HE), typically associated with cirrhosis and 
portal hypertension or portal-systemic shunts (PSS) [310]. C57BL/6J mice with high 
cerebral glutamine levels appeared to concomitantly have a PSS that resembled 
incomplete ductus venosus closure [212]. Cerebral glutamine levels were similar 
between mice that would later be identified as having a PSS or not at PN10, only 
mildly elevated at PN20, and grossly elevated from PN30 onwards [212]. PSS mice 
can be distinguished from non-PSS mice by performing portal angiography (a 
terminal procedure) or by measuring glutamine and myo-inositol levels in the brain 
[211, 212, 308]. Plasma ammonia, total bilirubin, and aspartate/alanine amino transferase 
were within normal limits in these mice [211, 308]. Brain glutamine concentration can 
be measured biochemically (post-mortem) or non-invasively via magnetic resonance 
spectroscopy (1H MRS) [211]. The spontaneous PSS could not be attributed to any 
environmental cause [211, 212]. Offspring of PSS mice did not show neurochemical 
anomalies, suggesting a non-Mendelian inheritance pattern [212]. It has been noted 
that two third of C57BL/6J Nrf2-/- mice have a congenital portacaval shunt. [311]. This 
is in contrast to WT C57BL/6J mice, where PSS is observed in “only” 25% of mice 
[211, 212]. In outbred ICR Nrf2-/- mice, PSS is not found, suggesting a complex multiple 
gene inheritance pattern of congenital PSS [311]. The metabolic consequences of 
portal blood directly entering the systemic circulation (i.e. PSS) are profound [211]. 
By inference, one would expect that the metabolic consequences of PSS are more 
severe in mice fed a high-carbohydrate diet versus a low-carbohydrate diet (i.e. a 
high-fat diet). Absorbed (long-chain) fats are carried via the lymphatic system into 
the vena cava. To an extent, the glycemic index of the diet determines the 
carbohydrate uptake rate. Semisynthetic diets typically contain carbohydrates with a 
high glycemic index (sucrose and maltodextrin) [118], whereas chow diets typically 
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only contain carbohydrates with a low glycemic index (starch). In rats with versus 
without PSS, the liver to body weight ratio is lower [312]. In dogs with a congenital 
PSS, liver volume rapidly normalizes after surgical correction (narrowing or full 
ligation of the shunt) [313]. Congenital PSS in WT C57BL/6J versus non-PSS is 
associated with delayed and less efficient postprandial glucose clearance and mild 
steatosis [211, 212]. Beyond these observations, congenital PSS of WT C57BL/6J has 
not been thoroughly characterized [211, 212]. PSS in C57BL/6J may be related to the 
aryl hydrocarbon receptor (Ahr) [212]. C57BL/6J mice express an allelic variant (Ahrb-
1) which translates into a high affinity ligand binding form of Ahr [314]. Other mouse 
strains express other allelic variants of Ahr, with a lower affinity [314]. Ahr knockout 
mice all have PSS (via patent ductus venosus), suggesting that Ahr plays a role in 
the resolution of fetal vascular structures during development [315]. In these mice, 
PSS correlates with a small liver sizer [315]. However, the inheritance pattern of Ahr 
and of WT PSS is different, and Ahr-KO mice have additional vascular anomalies 
not present in WT PSS mice [212, 315]. At this time it is not known what causes 
congenital PSS in WT C57BL/6J mice [211, 212]. The exclusion of mice with high 
cerebral glutamine, which can represent 25% of a given cohort, seems ethically 
challenging and scientifically questionable [306]. Cudalbu et al have raised questions 
regarding the suitability of the C57BL/6J mouse strain for neurobiology in absence 
of tools to screen the animals for high cerebral glutamine levels [212]. Soares et al 
indicated that, given the affected hepatic lipid content and glucose homeostasis, that 
the incidence of PSS in C57BL/6J affects should be taken into account [211]. 
 
Data in Chapter 6 show that heterogeneity in C57BL/6JOlaHsd can, to an extent, 
be explained by the presence of distinct subpopulations within cohorts [200]. These 
sub-cohorts are named ‘small liver’ (SL) and ‘normal liver’ (NL) for their most 
prominent feature upon initial identification [200]. Data in Chapter 6 suggest that the 
observed heterogeneity may be an inherent attribute of the C57BL/6JOlaHsd strain 
and possibly also the C57BL/6J mouse strain [200]. J and JOlaHsd are recognized as 
separate substrains which differ genetically and phenotypically [197]. Attributing the 
presence of the ‘SL’ phenotype solely to OlaHsd may be short-sighted as there are 
no clear data on its (non-) occurrence in C57BL/6J. As noted in studies using 
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apoE*3Leiden.CETP mice, it is possible that ‘SL’-like C57BL/6J mice are excluded 
from studies on suspicion of being statistical outliers. An outlier is an observation 
that appears to be inconsistent with other observations in the data set [316]. It would 
certainly be reasonable to assume that grossly inconsistent measurement values are 
more likely to originate from analytical errors than from seemingly random model-
specific idiosyncrasies. This is especially reasonable when group sizes are small, and 
the ‘SL’ phenomenon only occurs in 1 or 2 mice per group. The ‘SL’ phenotype is 
not discussed in Chapters 2-4. It is, nonetheless, present in all assessed cohorts, 
occurring approximately equally in eIMF and cIMF-fed mice. Curiously, the ‘SL’ 
phenotype appears to occur more often in LFD-fed versus HFD-fed cohorts. These 
mice had not been omitted from our analyses, and their presence did not alter the 
direction or the validity of any conclusion. The very nature of metabolic 
programming studies, i.e. (relatively) large group sizes, consistent usage of 
standardized (semisynthetic) diets, and long follow-up, likely created the perfect 
milieu to recognize the SL phenotype. Similarly, the ‘NR’ phenomenon was likely 
noticed in apoE*3Leiden.CETP mice as their phenotype (high plasma TG and TC) 
is grossly affected by differences in liver function [207]. 
 
The pathological liver condition described in Chapter 6 occurred in one third of 
C57BL/6J mice upon semisynthetic diet feeding. The condition correlates with low 
liver weight, low VLDL secretion (and low fasting plasma TG and TC), high plasma 
bile acids, liver steatosis, fibrosis and inflammation, and mitochondrial dysfunction 
[200]. The SL phenotype appears partially similar to what is observed when mice are 
infected with Helicobacter pylori [317], Helicobacter hepaticus or Helicobacter bilis 
[318]. Hepatic manifestations of Helicobacter infections typically show ballooning of 
hepatocytes, which is not seen in mice with the SL phenotype. Helicobacter agents 
are highly contagious. Mice with the SL condition occasionally share a cage with 
mice that do not have this liver condition. This does not fully rule out that the SL 
phenotype is not caused by an infectious etiologic agent. It is, nonetheless, unlikely 
that an infected mouse can share a cage with an uninfected mouse without 
transmitting its infectious agent. In the apoE*3Leiden.CETP casus, it was confirmed 
that mice with the ‘NR’ phenotype were not infected with Helicobacter [207]. The 
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importance of the gut microbiota for the phenotype of an individual is nowadays 
recognized by the scientific community [207, 319]. It may be that the microbiota play a 
role in the SL phenotype (or vice versa). Contrary to what one would expect, housing 
mice from different suppliers (with different microbiota compositions) in the same 
cage does not fully normalize their microbiota [319]. It is suggested that some aspects 
of the microbiota are established in early life and are difficult to displace post-
weaning due to limited transfer between animals [319]. Arguing for a microbiological 
origin of the ‘SL’ phenotype may, however, merely shift the issue of why ‘SL’ 
occurs towards why only certain mice exhibit phenotypes whereas others do not. 
 
At weaning (PN21), we have not been able to identify characteristic aspects of 
the SL phenotype, in contrast to the situation at PN42, when several parameters were 
discriminatory in one third of mice when fed a low-fat semisynthetic diet. It is not 
clear whether a similar phenomenon would occur upon standard chow feeding. Until 
such data is available, it is too speculative to conclude that the pathological condition 
occurs (in some mice) as a consequence of semisynthetic diet feeding. Regardless if 
this is the case, it would remain unclear why only certain mice develop this liver 
condition whereas others do not. It may be that specific experimental conditions 
amplify an otherwise unremarkable (epi)genetic heterogeneity. For maintaining a 
high standard of preclinical experimentation with the C57BL/6J mouse strain, 
identification of the cause of the SL phenotype would be very helpful. If the SL 
phenotype would only be manifested in (some) mice fed semisynthetic diet but not 
when fed chow, it may be possible to prevent the onset of the SL phenotype via the 
diet. If the SL phenotype is (epi)genetic, it may be possible to selectively breed the 
cause out of the C57BL/6J (epi)genome. It is, however, a possibility that congenital 
WT PSS, the ApoE*3Leiden.CETP ‘NR’ phenotype, and the WT C57BL/6JOlaHsd 
‘SL’ phenotype are all one and the same thing. If this is the case, it may explain that 
‘NR’ and ‘SL’ occur as a consequence of PSS, but not why (seemingly spontaneous) 
congenital PSS occurs. As the inheritance pattern of C57BL/6J congenital PSS is 
currently not understood, this may be the most significant problem associated with 
C57BL/6J inbreeding [212]. The acceptance of the existence of sub-cohorts would be 
a big step forward to understanding and preventing this source of significant 
heterogeneity and potential bias in preclinical research using C57BL/6J. 




An early life diet containing large phospholipid-coated lipid globules programs 
mice for a transiently lower body weight and fat mass gain later in life on high-fat 
diet [8]. The possible underlying mechanism is now hypothesized to be due to a long-
term modulation of postabsorptive lipid metabolism. The concept that postabsorptive 
lipid metabolism can affect adiposity and body weight is at this moment poorly 
understood, yet recognized as an important factor for energy expenditure and energy 
intake [97, 294, 296, 297]. These data indicate that infant milk formulae, despite currently 
achieving a high level of quality and safety [73], can be improved further (by 
modifying the physicochemical structure) for the benefit of infants who, for 
whatever reason, are not breast-fed [54]. 
 
Taken together, this thesis highlighted the prominent role of early life nutrition 
in determining adult life handling of fats. The way that dietary fat is ‘packaged’ in 
infant milk formula could be a powerful tool that can be used to improve long term 
(adult) health and potentially contribute to the prevention of various diseases of 
civilization. 
 
 
  
